Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

beclomethasone (QVAR RediHaler)

Notes:

^ adequate trial is defined as at least 2 weeks of treatment duration

<u>Initiation (new start) criteria</u>: Non-formulary <u>beclomethasone</u> (**QVAR RediHaler**) will be covered on the prescription drug benefit when the following criteria are met:

- Patient is at least 5 years of age.
- Patient has documented contraindication, intolerance, or treatment failure to an adequate[^] trial to ciclesonide (Alvesco), and either mometasone furoate (Asmanex HFA, Asmanex Twisthaler) or fluticasone propionate (Flovent HFA)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary beclomethasone
(QVAR RediHaler) will be covered on the prescription drug benefit when the following criteria are met:

- Patient is at least 5 years of age.
- Patient has documented contraindication, intolerance, or treatment failure to an adequate[^] trial to ciclesonide (Alvesco), and either mometasone furoate (Asmanex HFA, Asmanex Twisthaler) or fluticasone propionate (Flovent HFA)

kp.org

Revised: 09/12/24 Effective: 11/07/24



